Understand the source comparison
Glow Stack Skin Radiance Results Timeline: Peptide Stack Comparison
Palmitoyl Tripeptide-1 TGF-beta receptor agonist. Accelerates keratinocyte turnover 14–21 days Weeks 3–4 (surface brightness) Demonstrated 26% increase in cell proliferation markers in 28-day trial (Int J Cosmet Sci, 2019) Delivers early visible feedback but e
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Palmitoyl Tripeptide-1
- TGF-beta receptor agonist. Accelerates keratinocyte turnover
- 14–21 days
- Weeks 3–4 (surface brightness)
- Demonstrated 26% increase in cell proliferation markers in 28-day trial (Int J Cosmet Sci, 2019)
- Delivers early visible feedback but effect plateaus quickly. Front-load dosing in weeks 1–4
- Nonapeptide-1
- Competitive tyrosinase inhibitor. Blocks melanin synthesis
- 21–28 days (enzyme inhibition) / 42–56 days (visible effect)
- Weeks 8–12 (melanin regulation)
- Reduced melanin content by 48% vs control in 12-week study (J Cosmet Dermatol, 2021)
- The long latency to visible effect causes dropout. Requires user education on the delay between enzyme inhibition and surface manifestation
- Palmitoyl Pentapeptide-4
- Fibroblast stimulation. Increases collagen Types I and III production
- 28–35 days (synthesis initiation) / 56–84 days (structural density)
- Weeks 10–16 (dermal radiance)
- Increased procollagen synthesis 117% in cultured fibroblasts; 18% density gain at 12 weeks in vivo (Dermatol Surg, 2020)
- Produces the most durable radiance effect but the slowest to manifest. Must dose consistently through the invisible weeks 5–8
- Acetyl Hexapeptide-8
- SNARE complex inhibitor. Reduces microcontraction lines that scatter light
- 7–14 days
- Weeks 2–6 (optical smoothness)
- 27% reduction in periorbital line depth at 28 days (Cosmetics, 2018)
- Secondary radiance contributor. Improves surface light reflection but doesn't address pigment or structural density